Acorda Therapeutics Inc. (United States)

Acorda Therapeutics is a biotechnology company focused on developing therapies for neurological disorders. Headquartered in Ardsley, New York, Acorda is known for Ampyra (dalfampridine), an FDA-approved treatment that improves walking ability in patients with multiple sclerosis (MS). The company specializes in treatments for movement disorders, Parkinson’s disease, and spinal cord injuries, utilizing innovative drug delivery technologies to address unmet needs in neurology.